Endo Fha Avoid Bisphosphonates Denosumab Testosterone Leptin

---
name: endo-fha-avoid-bisphosphonates-denosumab-testosterone-leptin
description: This skill recommends against using bisphosphonates, denosumab, testosterone, or leptin to improve bone mineral density in adolescents and women with functional hypothalamic amenorrhea (FHA) due to insufficient evidence and potential risks. Use when a clinician asks, 'Should we give her denosumab for low BMD?' or encounters language such as 'Avoid bisphosphonates in FHA' or 'Do not use leptin or testosterone or leptin for bone health'.
---

# Avoid bisphosphonates, denosumab, testosterone, and leptin for BMD improvement in FHA

## STEP 1 — Gather Information for bone health'.
---

# Avoid bisphosphonates, denosumab, testosterone, and leptin for BMD improvement in FHA

## STEP 1 — Gather Information
Confirm FHA diagnosis (exclude pregnancy, thyroid disease, hyperprolactinemia, anatomic outflow tract anomalies); obtain baseline lumbar spine or hip BMD Z-score by DXA; document duration of amenorrhea, weight, BMI, exercise intensity, nutritional intake, and psychological stressors.

## STEP 2 — Rule In / Rule Out
If FHA is confirmed after excluding organic causes of amenorrhea, proceed to assess BMD; otherwise, stop and evaluate alternative diagnoses.

## STEP 3 — Classify or Stratify
Classify BMD status: Z-score > -1.0 (normal to low-normal) versus Z-score ≤ -1.0 (low BMD) or presence of a fragility fracture.

## STEP 4 — Decide
If Z-score ≤ -1.0 or a fragility fracture is present, recommend against bisphosphonates, denosumab, testosterone, or leptin; instead, initiate multidisciplinary therapy to correct energy imbalance (nutritional rehabilitation, cognitive behavioral therapy, exercise modification).

## Clinical Guardrails / Mimics / Pitfalls
Do not prescribe bisphosphonates, denosumab, testosterone, or leptin solely for BMD improvement in FHA due to lack of efficacy and potential fetal teratogenicity; avoid using oral contraceptive pills as the sole strategy for bone health; do not overlook persistent energy deficit as the primary driver of bone loss; monitor for stress fractures despite pharmacologic avoidance; consider that leptin administration may cause weight loss and worsen energy imbalance.

## Concrete Clinical Example
A 16‑year‑old female runner presents with 9 months of amenorrhea, BMI 16.8 kg/m2, lumbar spine Z‑score –1.8, and asks about denosumab for low BMD. After confirming FHA and excluding secondary causes, the clinician advises against denosumab and initiates a plan for increased caloric intake, weekly CBT, and reduced training volume.

**Source:** Functional Hypothalamic Amenorrhea: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2017, DOI:10.1210/jc.2017-00131